3SBio's (HKG:1530) unit Shenyang Sunshine Pharmaceutical has agreed to obtain the exclusive commercialization rights of Sunshine Lake Pharma's clifutinib besylate for specific indications in Mainland China, a Monday bourse filing said.
Under the contract, Shenyang Sunshine Pharmaceutical will pay Sunshine Lake Pharma an initial payment as well as certain R&D and sales milestone payments.
Sunshine Lake Pharma will continue to be responsible for the research and development, registration, production, and other works related to the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.